2 studies found for:    MOXR0916
Show Display Options
Rank Status Study
1 Recruiting A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Intervention: Drug: MOXR0916
2 Recruiting A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody;   Drug: Bevacizumab, a recombinant humanised anti-VEGF (vascular endothelial growth factor) monoclonal antibody;   Drug: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody

Study has passed its completion date and status has not been verified in more than two years.